Disease · MONDO_0019473

enteropathy-associated T-cell lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. enteropathy-associated T-cell lymphoma. Diseases, record MONDO_0019473. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019473

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: enteropathy-associated T-cell lymphoma; Open Targets
Open Targets ID: MONDO_0019473; Open Targets
Other names: EATL, EATL, type I, ETTL, enteropathy-associated T-cell lymphoma, type I, enteropathy-type T-cell lymphoma, intestinal T-cell lymphoma; Open Targets
MeSH: D058527; MeSH
NCI Thesaurus: C4737; NCI Thesaurus
Orphanet: ORPHA:86880; Orphanet
Highest stage of its drugs: Phase 2/3, for 1 of its 26 drugs, from ClinicalTrials.gov; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ZANOLIMUMAB	CHEMBL2108063	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets42

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	4	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 42

See all 42 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02561273	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Phase 1/2	54	2021-06-18	Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, LENALIDOMIDE, PREDNISONE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT03049449	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Phase 1	26	2022-05-25	Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Peripheral	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT01719835	CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study	Phase 2	87		Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic Gamma/ Delta T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma	CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, GEMCITABINE, METHYLPREDNISOLONE, PREDNISOLONE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00669812	High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma	Phase 2	60		Lymphoma, Small Intestine Cancer	CARMUSTINE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE, ETOPOSIDE, IFOSFAMIDE, MELPHALAN, METHOTREXATE, PREDNISOLONE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT07055477	A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	Phase 1	60		Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Monomorphic Epithelialtropic Intestinal Lymphoma, Enteropathy Associated T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Subacute Panniculitis-like T-cell Lymphoma	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT06211881	Chi-GVM Regimen for the Treatment of R/R PTCL	Not applicable	50		Relapsed/Refractory Peripheral T-cell Lymphoma	GEMCITABINE, TUCIDINOSTAT, VINORELBINE	Its record names the disease	ClinicalTrials.gov
NCT00322985	A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma	Phase 2	40		T-cell Lymphoma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00877656	HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma	Phase 2/3	21		T Cell Lymphoma	ZANOLIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT03217643	CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.	Phase 2	14		Enteropathy Associated T-cell Lymphoma	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT06701344	Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients	Phase 2	7		Enteropathy Associated T Cell Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN, GOLIDOCITINIB, PREDNISONE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): deaths from any cause	9 of 39	1 of 4	43	NCT02561273	Trial comparisons
Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): serious adverse events	14 of 39	2 of 4	43	NCT02561273	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37939262	DERIVED	1	PubMed
30104718	DERIVED	1	PubMed
29703335	DERIVED	1	PubMed
25355245	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019473

GET https://conductscience.org/api/diseases/v1/MONDO_0019473/drugs?page=2

API reference For AI assistants